Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IXICOPHYOF -53.33%42 Debt-to-Equity is 0.05 as of Mar. 2026, which is 25% above its 10-year median of 0.04. GuruFocus rates PHYOF with a GF Score™ of 42/100 and a GF Value™ of $0.07. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, IXICO ranks better than 72.05% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for IXICO's Debt-to-Equity or its related term are showing as below:
PHYOF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.06
Current: 0.05
During the past 13 years, the highest Debt-to-Equity Ratio of IXICO was 0.06. The lowest was 0.02. And the median was 0.04.
PHYOF's Debt-to-Equity is ranked better than 72.05% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs PHYOF: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
IXICO Debt-to-Equity Related Terms
IXICO Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for IXICO's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHYOF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, IXICO's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IXICO Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IXICO's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where IXICO's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IXICO (PHYOF) has a Debt-to-Equity of 0.05 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on IXICO and its competitors. This is 25% above median its historical median of 0.04. Over the past decade, IXICO's Debt-to-Equity has ranged from 0.02 to 0.06. According to the industry distribution chart, IXICO ranks #270 out of 966 companies in the Biotechnology industry, placing it in the top 28%.
Is IXICO's Debt-to-Equity too high?
IXICO's current Debt-to-Equity of 0.05 is 25% above median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.06. The Biotechnology industry median Debt-to-Equity is 0.16. IXICO's value of 0.05 is 68.8% below this industry median. Based on the distribution chart, IXICO ranks #270 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IXICO has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does IXICO's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IXICO ranks #270 out of 966 companies for Debt-to-Equity. This puts IXICO in the upper half of its industry. The industry median Debt-to-Equity is 0.16. IXICO's value of 0.05 is 68.8% below this benchmark. Historically, IXICO's own Debt-to-Equity has ranged from 0.02 to 0.06 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.16, IXICO has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IXICO's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on IXICO and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IXICO's current Debt-to-Equity is 0.05, which is 25% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IXICO stock overvalued right now?
IXICO (PHYOF) has a current Debt-to-Equity of 0.05. The stock's GF Value™ is $0.07, compared to a current price of $0.07 — trading right at its estimated fair value. The current Debt-to-Equity is 0.05, which is 25% above median its 10-year median of 0.04 and 68.8% below the Biotechnology industry median of 0.16. IXICO's overall GF Score™ is 42/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For IXICO (PHYOF), the current Debt-to-Equity is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IXICO (PHYOF) Overvalued in 2026?
Based on GuruFocus' analysis, IXICO stock appears to be undervalued.
The current stock price of $0.07 is trading 0% below its estimated GF Value™ of $0.07.
Key valuation signals for PHYOF:
Debt-to-Equity: 0.05 (25% above median its 10-year median of 0.04)
GF Value™: $0.07 vs. price of $0.07 (0% below fair value)
Industry Position: 68.8% below the Biotechnology median (#270 of 966)
No single metric tells the full story. See the PHYOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IXICO PLC provides neuroscience imaging and biomarker analytics services, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. It operates as an imaging contract research organization, supporting clinical trials for neurological disorders by processing and analyzing imaging data. Its platform is used to measure biomarkers associated with diseases such as Alzheimer's, Huntington's, and Parkinson's.
42GF Score
Get the complete analysis for PHYOF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHYOF has been successfully added to your 
